@article{MTMT:34034279,
	title = {PARP2 promotes inflammation in psoriasis by modulating estradiol biosynthesis in keratinocytes},
	url = {https://m2.mtmt.hu/api/publication/34034279},
	author = {Antal, Dóra and Pór, Ágnes and Kovács, Ilona and Dull, Katalin and Póliska, Szilárd and Ujlaki, Gyula and Demény, Máté Ágoston and Szöllősi, Attila and Kiss, Borbála and Szegedi, Andrea and Bay, Péter and Szántó, Magdolna},
	doi = {10.1007/s00109-023-02338-z},
	journal-iso = {J MOL MED-JMM},
	journal = {JOURNAL OF MOLECULAR MEDICINE-JMM},
	volume = {101},
	unique-id = {34034279},
	issn = {0946-2716},
	year = {2023},
	eissn = {1432-1440},
	pages = {987-999},
	orcid-numbers = {Pór, Ágnes/0000-0002-2945-0684; Kovács, Ilona/0000-0003-0629-5615; Dull, Katalin/0000-0001-5594-0364; Póliska, Szilárd/0000-0002-9722-251X; Szöllősi, Attila/0000-0001-6046-8236; Kiss, Borbála/0000-0002-6076-9984; Szegedi, Andrea/0000-0003-2109-9014}
}

@article{MTMT:32628668,
	title = {The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of HER2 positive breast cancer cells to trastuzumab-mediated ADCC},
	url = {https://m2.mtmt.hu/api/publication/32628668},
	author = {Guti, Eliza and Regdon, Zsolt and Sturniolo, Isotta and Kiss, Alexandra and Kovács, Katalin and Demény, Máté Ágoston and Szöőr, Árpád and Vereb, György and Szöllősi, János and Hegedűs, Csaba and Polgár, Zsuzsanna and Virág, László},
	doi = {10.1007/s00262-022-03146-z},
	journal-iso = {CANCER IMMUNOL IMMUN},
	journal = {CANCER IMMUNOLOGY IMMUNOTHERAPY},
	volume = {71},
	unique-id = {32628668},
	issn = {1432-0851},
	abstract = {Despite recent advances in the development of novel personalized therapies, breast cancer continues to challenge physicians with resistance to various advanced therapies. The anticancer action of the anti-HER2 antibody, trastuzumab, involves antibody-dependent cell-mediated cytotoxicity (ADCC) by natural killer (NK) cells. Here, we report a repurposing screen of 774 clinically used compounds on NK-cell + trastuzumab-induced killing of JIMT-1 breast cancer cells. Using a calcein-based high-content screening (HCS) assay for the image-based quantitation of ADCC that we have developed and optimized for this purpose, we have found that the multitargeted tyrosine kinase inhibitor sunitinib inhibits ADCC in this model. The cytoprotective effect of sunitinib was also confirmed with two other assays (lactate dehydrogenase release, and electric cell substrate impedance sensing, ECIS). The drug suppressed NK cell activation as indicated by reduced granzyme B deposition on to the target cells and inhibition of interferon-γ production by the NK cells. Moreover, sunitinib induced downregulation of HER2 on the target cells' surface, changed the morphology and increased adherence of the target cells. Moreover, sunitinib also triggered the autophagy pathway (speckled LC3b) as an additional potential underlying mechanism of the cytoprotective effect of the drug. Sunitinib-induced ADCC resistance has been confirmed in a 3D tumor model revealing the prevention of apoptotic cell death (Annexin V staining) in JIMT-1 spheroids co-incubated with NK cells and trastuzumab. In summary, our HCS assay may be suitable for the facile identification of ADCC boosting compounds. Our data urge caution concerning potential combinations of ADCC-based immunotherapies and sunitinib.},
	keywords = {breast cancer; natural killer cell; trastuzumab; sunitinib; antibody-dependent cell mediated cytotoxicity (ADCC); Herceptin},
	year = {2022},
	eissn = {0340-7004},
	pages = {2151-2168}
}

@article{MTMT:31672523,
	title = {PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer},
	url = {https://m2.mtmt.hu/api/publication/31672523},
	author = {Curtin, Nicola and Bay, Péter},
	doi = {10.3390/cancers12123494},
	journal-iso = {CANCERS},
	journal = {CANCERS},
	volume = {12},
	unique-id = {31672523},
	year = {2020},
	eissn = {2072-6694},
	pages = {3494}
}

@article{MTMT:31669676,
	title = {The Proteasome Activators Blm10/PA200 Enhance the Proteasomal Degradation of N-Terminal Huntingtin},
	url = {https://m2.mtmt.hu/api/publication/31669676},
	author = {Aladdin, Azzam and Yao, Yanhua and Yang, Ciyu and Kahlert, Günther and Ghani, Marvi and Király, Nikolett and Boratkó, Anita and Uray (Davis), Karen L. and Dittmar, Gunnar and Tar, Krisztina},
	doi = {10.3390/biom10111581},
	journal-iso = {BIOMOLECULES},
	journal = {BIOMOLECULES},
	volume = {10},
	unique-id = {31669676},
	issn = {2218-273X},
	year = {2020},
	eissn = {2218-273X},
	pages = {1581}
}

@article{MTMT:31627406,
	title = {Indoxylsulfate, a metabolite of the microbiome, has cytostatic effects in breast cancer via activation of AHR and PXR receptors and induction of oxidative stress},
	url = {https://m2.mtmt.hu/api/publication/31627406},
	author = {Sári, Zsanett Mercédesz and Mikó, Edit and Kovács, Tünde and Boratkó, Anita and Ujlaki, Gyula and Jankó, Laura and Kiss, Borbála Katalin and Uray (Davis), Karen L. and Bay, Péter},
	doi = {10.3390/cancers12102915},
	journal-iso = {CANCERS},
	journal = {CANCERS},
	volume = {12},
	unique-id = {31627406},
	year = {2020},
	eissn = {2072-6694}
}

@article{MTMT:31607797,
	title = {Fecal expression of Escherichia coli lysine decarboxylase (LdcC) is downregulated in E-cadherin negative lobular breast carcinoma},
	url = {https://m2.mtmt.hu/api/publication/31607797},
	author = {Sári, Zsanett Mercédesz and Kovács, Tünde and Csonka, Tamás and Török, M and Sebő, É and Toth, J and Tóth, Dezső and Mikó, Edit and Kiss, Borbála Katalin and Szeőcs, Dóra and Uray (Davis), Karen L. and Karányi, Zsolt and Kovács, Ilona and Méhes, Gábor and Árkosy, Péter and Bay, Péter},
	doi = {10.1556/2060.2020.00016},
	journal-iso = {PHYSIOL INT},
	journal = {PHYSIOLOGY INTERNATIONAL},
	volume = {107},
	unique-id = {31607797},
	issn = {2498-602X},
	year = {2020},
	eissn = {2677-0164},
	pages = {349-358}
}

@article{MTMT:31408732,
	title = {Glycogen phosphorylase inhibitor, 2,3-bis[(2E)-3-(4-hydroxyphenyl)prop-2-enamido] butanedioic acid (BF142), improves baseline insulin secretion of MIN6 insulinoma cells},
	url = {https://m2.mtmt.hu/api/publication/31408732},
	author = {Nagy, Lilla Nikoletta and Béke, F and Juhász, László and Kovács, Tünde and Juhászné Tóth, Éva and Docsa, Tibor and Tóth, Attila and Somsák, László and Bay, Péter},
	doi = {10.1371/journal.pone.0236081},
	journal-iso = {PLOS ONE},
	journal = {PLOS ONE},
	volume = {15},
	unique-id = {31408732},
	issn = {1932-6203},
	abstract = {Type 2 diabetes mellitus (T2DM), one of the most common metabolic diseases, is characterized by insulin resistance and inadequate insulin secretion of beta cells. Glycogen phosphorylase (GP) is the key enzyme in glycogen breakdown, and contributes to hepatic glucose production during fasting or during insulin resistance. Pharmacological GP inhibitors are potential glucose lowering agents, which may be used in T2DM therapy. A natural product isolated from the cultured broth of the fungal strain No. 138354, called 2,3-bis(4-hydroxycinnamoyloxy)glutaric acid (FR258900), was discovered a decade ago. In vivo studies showed that FR258900 significantly reduced blood glucose levels in diabetic mice. We previously showed that GP inhibitors can potently enhance the function of beta cells. The purpose of this study was to assess whether an analogue of FR258900 can influence beta cell function. BF142 (Meso-Dimethyl 2,3-bis[(E)-3-(4-acetoxyphenyl)prop-2-enamido]butanedioate) treatment activated the glucose-stimulated insulin secretion pathway, as indicated by enhanced glycolysis, increased mitochondrial oxidation, significantly increased ATP production, and elevated calcium influx in MIN6 cells. Furthermore, BF142 induced mTORC1-specific phosphorylation of S6K, increased levels of PDX1 and insulin protein, and increased insulin secretion. Our data suggest that BF142 can influence beta cell function and can support the insulin producing ability of beta cells.},
	year = {2020},
	eissn = {1932-6203},
	orcid-numbers = {Juhász, László/0000-0002-7462-7944; Somsák, László/0000-0002-9103-9845}
}

@article{MTMT:31408725,
	title = {Indolepropionic acid, a metabolite of the microbiome, has cytostatic properties in breast cancer by activating AHR and PXR receptors and inducing oxidative stress},
	url = {https://m2.mtmt.hu/api/publication/31408725},
	author = {Sári, Zsanett Mercédesz and Mikó, Edit and Kovács, Tünde and Jankó, Laura and Csonka, Tamás and Lente, G and Sebő, É and Toth, J and Tóth, Dezső and Árkosy, Péter and Boratkó, Anita and Ujlaki, Gyula and Török, M and Kovács, Ilona and Szabó, Judit and Kiss, Borbála Katalin and Méhes, Gábor and Goedert, JJ and Bay, Péter},
	doi = {10.3390/cancers12092411},
	journal-iso = {CANCERS},
	journal = {CANCERS},
	volume = {12},
	unique-id = {31408725},
	year = {2020},
	eissn = {2072-6694}
}

@article{MTMT:31334758,
	title = {The voltage-gated proton channel hHv1 is functionally expressed in human chorion-derived mesenchymal stem cells},
	url = {https://m2.mtmt.hu/api/publication/31334758},
	author = {Mészáros, Beáta and Papp, Ferenc and Mocsár, Gábor and Kókai, Endre and Kovács, Katalin and Tajti, Gábor and Panyi, György},
	doi = {10.1038/s41598-020-63517-3},
	journal-iso = {SCI REP},
	journal = {SCIENTIFIC REPORTS},
	volume = {10},
	unique-id = {31334758},
	issn = {2045-2322},
	year = {2020},
	eissn = {2045-2322},
	orcid-numbers = {Panyi, György/0000-0001-6227-3301}
}

@article{MTMT:31307373,
	title = {The proteasome activator PA200 regulates expression of genes involved in cell survival upon selective mitochondrial inhibition in neuroblastoma cells},
	url = {https://m2.mtmt.hu/api/publication/31307373},
	author = {DOUIDA, ABDENNOUR and Batista, F and Robaszkiewicz, A and Botó, Pál and Aladdin, Azzam and Szenykiv, M and Czinege, R and Virág, László and Tar, Krisztina},
	doi = {10.1111/jcmm.15323},
	journal-iso = {J CELL MOL MED},
	journal = {JOURNAL OF CELLULAR AND MOLECULAR MEDICINE},
	volume = {24},
	unique-id = {31307373},
	issn = {1582-1838},
	year = {2020},
	eissn = {1582-4934},
	pages = {6716-6730}
}